Nuke661, thanks for sharing the response from IR! Clearly shows that the "disconnect" is a non-issue. He did state that "As far as the trigger points for those data points, these are event-driven endpoints, and it's good for patients the longer they go out."
These even-driven endpoints did in fact get extended out not once, but twice and yes, good for the patients!
This is clearly shown as the corporate fact sheet needed to be updated twice alrady! so whats good for patients as SK said... is good for the shareholders!
Nuke, Thanks for helping to calrify the disconnect statement.
Regarding the not moving the needle thread which has been rehashed many times on the board, has anyone besides me ever used terminology in a conversation that they came to regret (as in it is not what you intended to infer or mean). I have done this on a number of occasions and believe this to be the case in this instance. What could be true and what I have tried to clarify in past posts is that the move the needle comment was initially partly misinterpreted and was later clarified by IR to have meant with regards to partnering discussions as compared to the more robust randomized double blind second line trial that most potential partners were more focused on. Like you I have E-mails from IR that will back up what I am saying. I will wait until after front line results come out to post the proof. I am a dedicated hard core long with a lot invested here and have never sold a share. I remain positive overall and hopeful we will will get good needle moving news soon.
News 
Market Data 
Discover 
AI
